Study reveals potential new target for treating acute myeloid leukaemia

Pinterest LinkedIn Tumblr +

Bone marrow failure due to acute myeloid leukaemia (AML) is a significant factor behind the disease’s high rate of morbidity and mortality.

Previous studies in mice suggest that AML cells inhibit healthy haematopoietic (blood) stem and progenitor cells (HSPC).

A study released in STEM CELLS adds to this extent of knowledge by showing how secreted cell factors, in particular a protein called transforming growth factor beta 1 (TGFβ1), leads to a breakdown in the production of healthy blood cells (a process called hematopoiesis) in humans.

The study’s findings indicate that blocking TGFβ1 could improve haematopoiesis in AML patients.

Although AML makes up only about 1 percent of all cancers, it is the second most common type of leukaemia diagnosed, according to the American Cancer Society. AML affects the blood and bone marrow – the spongy tissue inside bones where blood cells are made.

The mortality rate is high – for those aged 20 and older, the five-year survival rate is a dismal 26 percent.

The mechanisms by which AML develops are not completely understood, but it is generally believed to begin in the haemopoietic stem cells or progenitors, which develop into myeloid cells and in turn go on to become red blood cells, white blood cells or platelets.

This latest study, by researchers at Heinrich-Heine-University Düsseldorf, was designed to investigate what role fluids secreted by leukaemic cells might play in inhibiting the growth of healthy haematopoietic stem and HSPC.

“Experiments using conditioned media (CM) from AML cells to address secretory mechanisms have been performed before, but mainly in mice.

In order to gain new insights into how this plays out in humans, we focused on the interaction between leukaemic cells and healthy HSPC using an in vitro system modelling the in vivo situation of bone marrow infiltration by AML cells,” said the study’s corresponding author, Thomas Schroeder, M.D., Ph.D., Department of Hematology, Oncology and Clinical Immunology.

This was accomplished by exposing healthy bone marrow-derived CD34 HSPC to supernatants derived from AML cell lines and newly diagnosed AML patients. (CD34 is a marker of human HSC, while supernatants are the products secreted by cells.)

“Our findings revealed that exposure to AML-derived supernatants significantly inhibited proliferation, cell cycling, colony formation and differentiation of healthy CD34 HSPC,” Dr. Schroeder reported. “Further experiments determined that leukaemic cells induce functional inhibition of healthy HSPC, at least in part through TGFβ1.

“Blocking the TGFβ1 pathway is something that could be pharmacologically accomplished with a TGFβ1 inhibitor such as SD208. Our data indicate this could be a promising approach to improve haematopoiesis in AML patients.”

Dr. Jan Nolta, Editor-in-Chief of STEM CELLS, said, “finding factors for possible intervention in the perplexing issue of suppression of normal haematopoiesis by AML cells is highly important. The possibility of targeting TGFβ1 in order to allow the normal stem and progenitor cells to expand is a promising lead toward future treatments.”

Source: Alphamed Press


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.